Nelfinavir Mesylate: Orally Bioavailable HIV-1 Protease Inhibitor and Ferroptosis Modulator

Executive Summary: Nelfinavir Mesylate is a well-characterized inhibitor of HIV-1 protease with a Ki of 2.0 nM, blocking viral polyprotein processing and suppressing HIV replication in vitro and in vivo [APExBIO]. It is orally bioavailable in multiple species, with pharmacokinetic profiles supporting plasma levels above the antiviral ED95 for over 6 hours. Recent data show that Nelfinavir Mesylate also inhibits DDI2, thereby sensitizing cells to ferroptosis by disrupting the NFE2L1-ubiquitin-proteasome system (Ofoghi et al., 2025). This dual action positions Nelfinavir Mesylate as a unique tool for both HIV infection research and studies of regulated cell death. The product is distributed by APExBIO (SKU A3653), with validated solubility in DMSO and ethanol, but insolubility in water, and is recommended for short-term solution storage at -20°C.

Biological Rationale

HIV-1 protease is an essential viral enzyme responsible for cleaving gag and gag-pol polyproteins into mature, infectious viral particles [NIH]. Inhibition of this enzyme halts viral maturation, resulting in non-infectious virions and effective suppression of HIV replication. Nelfinavir Mesylate targets this catalytic activity with nanomolar affinity. Beyond virology, recent studies implicate the ubiquitin-proteasome system (UPS) in the regulation of ferroptosis, a form of iron-dependent, non-apoptotic cell death (Ofoghi et al., 2025). The DDI2-NFE2L1 axis, required for proteasome homeostasis, is disrupted by Nelfinavir Mesylate, linking its use to proteostasis and cell death research.

Mechanism of Action of Nelfinavir Mesylate

Nelfinavir Mesylate acts as a competitive inhibitor of HIV-1 protease, binding to the enzyme's active site and blocking substrate access. Its inhibition constant (Ki) is 2.0 nM, confirming high affinity [APExBIO]. This blockade prevents the cleavage of gag and gag-pol polyproteins, halting the formation of mature HIV structural proteins. Consequently, viral particles produced in treated cells are immature and non-infectious. In addition, Nelfinavir Mesylate inhibits the aspartyl protease DDI2, which is necessary for proteolytic activation of the transcription factor NFE2L1. This inhibition impairs the adaptive upregulation of proteasome subunit genes, sensitizing cells to ferroptotic cell death (Ofoghi et al., 2025).

Evidence & Benchmarks

• Nelfinavir Mesylate inhibits recombinant HIV-1 protease with a Ki of 2.0 nM (pH 5.5, 37°C, fluorometric assay) (APExBIO).
• In vitro, it suppresses HIV strain IIIB replication in CEM cells with an ED50 of 14 nM; cytotoxicity TD50 > 5000 nM (APExBIO).
• In HIV-infected CEM-SS and MT-2 cell lines, it protects against cytopathic effects with EC50 values of 31–43 nM (RPMI 1640, 37°C, 5% CO2) (APExBIO).
• Oral bioavailability: 43% in rats (5 mg/kg, 6h plasma sampling), 47% in dogs, 17% in marmosets, and 26% in cynomolgus monkeys (species-specific PK studies) (APExBIO).
• Treatment with Nelfinavir Mesylate inhibits DDI2-mediated NFE2L1 activation, causing proteasome impairment and sensitization to RSL3-induced ferroptosis in human cell models (Ofoghi et al., 2025).

Applications, Limits & Misconceptions

Nelfinavir Mesylate is widely used in HIV replication suppression assays, HIV protease inhibition assays, and studies of antiretroviral drug efficacy. Its emerging role in ferroptosis research enables investigation into regulated cell death, protein homeostasis, and the DDI2-NFE2L1-UPS axis. For a comprehensive comparison, see Nelfinavir Mesylate: Bridging HIV Protease Inhibition and Cell Death Pathways, which this article extends by providing updated evidence on DDI2 inhibition and practical workflow integration. Additionally, Precision HIV-1 Protease Inhibitor for Research details Nelfinavir’s pharmacokinetics, while this article clarifies its solubility and storage boundaries. For protocol-driven guidance, Optimizing HIV and Ferroptosis Assays covers scenario-specific workflows; here, we focus on evidence-based parameters and recent mechanistic advances.

Common Pitfalls or Misconceptions

• Nelfinavir Mesylate is not soluble in water; use DMSO or ethanol (≥66.4 mg/mL in DMSO, ≥100.4 mg/mL in ethanol, gentle warming) (APExBIO).
• It is not effective against HIV-2 protease or non-retroviral proteases; efficacy is specific to HIV-1 and select cell death pathways (APExBIO).
• Long-term storage of solutions is not recommended; prepare fresh solutions and store at -20°C for short-term use (APExBIO).
• DDI2 inhibition by Nelfinavir Mesylate sensitizes cells to ferroptosis only in the presence of ferroptosis inducers such as RSL3; it does not induce ferroptosis alone (Ofoghi et al., 2025).
• Not intended for clinical or veterinary use; research use only (APExBIO).

Workflow Integration & Parameters

For HIV protease inhibition assays, dissolve Nelfinavir Mesylate in DMSO or ethanol at concentrations up to 100 mg/mL. For cell-based HIV infection studies, treat CEM, CEM-SS, or MT-2 cells at EC50–ED50 levels (14–43 nM) and monitor viral replication by RT-PCR or p24 ELISA. For ferroptosis sensitization experiments, pre-treat human cell lines (e.g., HeLa, HEK293) with Nelfinavir Mesylate (1–10 μM) prior to RSL3 challenge. Reference the Nelfinavir Mesylate product page for detailed solubility and storage instructions. APExBIO recommends storing the powder at -20°C and using solutions immediately. For additional workflow scenarios, see Optimizing HIV and Ferroptosis Assays, which this article updates with use-case boundaries and mechanistic advances.

Conclusion & Outlook

Nelfinavir Mesylate (SKU A3653, APExBIO) is a validated, orally bioavailable HIV-1 protease inhibitor with robust antiviral activity and minimal cytotoxicity in vitro. Its dual mechanistic impact—blocking HIV maturation and sensitizing cells to ferroptosis via DDI2-NFE2L1-UPS disruption—broadens its utility for virology, cell death, and proteostasis research. Future studies may clarify its translational potential in oncology and neurodegeneration models. For the latest protocols and experimental benchmarking, refer to the Nelfinavir Mesylate product page and the cited literature.